S
Synlogic
Medicines to perform metabolic functions to treat diseases throughout the body
About Synlogic
Synlogic, Inc. operates in the biotechnology sector, focusing on the development of synthetic biology-based therapeutics. The company engineers bacteria to perform specific functions within the human body, targeting complex diseases that are difficult to treat with traditional methods. Synlogic's primary clients include healthcare providers and pharmaceutical companies. The company operates in the global healthcare market, leveraging its proprietary technology to create novel treatments. Synlogic generates revenue through research and development partnerships, grants, and potential future product sales. Key products in development include SYNB1891, aimed at stimulating immune responses in challenging tumors.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- Cambridge, United States
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Atlas Venture
NEA
Bill & Melinda Gates Foundation
OrbiMed
Series B and later7 investors entered at this stage
Rock Springs Capital
Ally Bridge Group
Aju IB Investment
Deerfield
CLI Ventures
Perceptive Advisors
Ginkgo Bioworks
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Synlogic on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Synlogic on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.